← Back to Screener
Sonoma Pharmaceuticals, Inc. Common Stock (SNOA)
Price$2.65
Favorite Metrics
Price vs S&P 500 (26W)-51.82%
Price vs S&P 500 (4W)-14.84%
Market Capitalization$4.59M
All Metrics
Book Value / Share (Quarterly)$1.98
P/TBV (Annual)0.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)4.20%
Cash Flow / Share (Quarterly)$-2.15
Price vs S&P 500 (YTD)-40.95%
Gross Margin (TTM)38.16%
Net Profit Margin (TTM)-19.02%
EPS (TTM)$-2.04
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-2.04
Revenue Growth (5Y)-4.44%
EPS (Annual)$-2.79
ROI (Annual)-74.65%
Gross Margin (Annual)38.25%
Net Profit Margin (5Y Avg)-32.50%
Cash / Share (Quarterly)$1.48
Revenue Growth QoQ (YoY)22.03%
ROA (Last FY)-25.25%
Revenue Growth TTM (YoY)26.83%
EBITD / Share (TTM)$-2.00
ROE (5Y Avg)-70.78%
Operating Margin (TTM)-15.61%
Cash Flow / Share (Annual)$-0.10
P/B Ratio1.34x
P/B Ratio (Quarterly)1.80x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.11x
Net Interest Coverage (TTM)-5.10x
ROA (TTM)-24.17%
EPS Incl Extra (Annual)$-2.79
Current Ratio (Annual)3.09x
Quick Ratio (Quarterly)1.21x
3-Month Avg Trading Volume0.02M
52-Week Price Return-2.54%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.10
P/S Ratio (Annual)0.32x
Asset Turnover (Annual)1.04x
52-Week High$6.92
Operating Margin (5Y Avg)-31.34%
EPS Excl Extra (Annual)$-2.79
CapEx CAGR (5Y)-17.55%
Tangible BV CAGR (5Y)-12.24%
26-Week Price Return-43.07%
Quick Ratio (Annual)2.28x
13-Week Price Return-29.88%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)2.88x
Enterprise Value$2.025
Revenue / Share Growth (5Y)-1.01%
Asset Turnover (TTM)1.27x
Book Value / Share Growth (5Y)-3.09%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.13x
Pretax Margin (Annual)-20.35%
Cash / Share (Annual)$3.29
3-Month Return Std Dev62.29%
Gross Margin (5Y Avg)36.14%
Net Income / Employee (TTM)$-0
ROE (Last FY)-78.37%
Net Interest Coverage (Annual)-327.00x
EPS Basic Excl Extra (Annual)$-2.79
P/FCF (TTM)4.38x
Receivables Turnover (TTM)7.40x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.04
Receivables Turnover (Annual)5.57x
ROI (TTM)-83.72%
P/S Ratio (TTM)0.26x
Pretax Margin (5Y Avg)-32.55%
Revenue / Share (Annual)$11.51
Tangible BV / Share (Annual)$1.62
Price vs S&P 500 (52W)-37.64%
Year-to-Date Return-36.81%
5-Day Price Return-2.13%
EPS Normalized (Annual)$-2.79
ROA (5Y Avg)-28.63%
Net Profit Margin (Annual)-24.20%
Month-to-Date Return7.98%
Cash Flow / Share (TTM)$-1.37
EBITD / Share (Annual)$-2.43
Operating Margin (Annual)-25.97%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-63.72%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.04
P/TBV (Quarterly)0.41x
P/B Ratio (Annual)0.80x
Inventory Turnover (TTM)3.20x
Pretax Margin (TTM)-19.47%
Book Value / Share (Annual)$2.70
Price vs S&P 500 (13W)-32.74%
Beta1.76x
P/FCF (Annual)5.15x
Revenue / Share (TTM)$10.35
ROE (TTM)-85.94%
52-Week Low$2.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SNOASonoma Pharmaceuticals, Inc. Common Stock | 0.26x | -4.44% | 38.16% | -15.61% | $2.65 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Sonoma Pharmaceuticals is a specialty pharmaceutical company focused on medical dermatology, developing therapies for chronic skin conditions including acne, atopic dermatitis, and scarring. Its product portfolio includes Celacyn, Mondoxyne, Alevicyn, Microcyn, and Ceramax Skin Barrier Cream, treating conditions such as scars, itchy skin, and minor irritations. The company generates revenue from product sales in the United States, Latin America, Europe, and Asia.